Research Topics - Oncology

Advancing research for

oncology Research

Join ONEASAs dedicated research to shape advancing cancer

care through diversity and innovation.

Mortality and Burden of Cancer in Indonesia

Mortality

Burden (USD, M)

Mortality and Burden of Cancer in Indonesia

In Indonesia, as in many other nations, cancer stands as a major public health concern, with the most prevalent types including breast, cervical, lung, colorectal, and liver cancer. The country encounters distinct obstacles in cancer care, such as limited access to programs for early detection, a deficit in healthcare facilities and oncology specialists, and the prohibitive costs associated with treatment. Furthermore, a general lack of awareness regarding cancer prevention and the importance of early detection contributes to diagnoses at advanced stages and diminished survival rates. Consequently, the advancement of oncology in Indonesia is geared towards enhancing early detection and screening initiatives, raising public awareness about cancer, and improving the healthcare system along with making treatments more accessible and affordable. Additionally, there is an increasing inclination towards combining traditional and modern cancer treatment methods to offer comprehensive care to patients. The field of clinico-genomic research holds considerable promise for oncology in Indonesia by pinpointing genetic and molecular markers unique to the Indonesian populace that influence cancer susceptibility, progression, and response to treatment. Our studies aim to facilitate personalized treatment approaches, which could significantly enhance treatment efficacy and potentially lower death rates. Moreover, by elucidating the genetic characteristics of prevalent cancers in Indonesia, such as those of the breast, lung, and cervix, we can develop focused strategies for screening and prevention, ultimately leading to improved health outcomes.

Source

https://cdn.who.int/media/docs/default-source/country-profiles/ncds/idn_en.pdf?sfvrsn=fbb0cdfb_33&download=true

https://www.iccp-portal.org/system/files/plans/IDN_2020.pdf

https://databoks.katadata.co.id/datapublish/2023/07/03/bpjs-kesehatan-kucurkan-rp24-triliun-untuk-penyakit-katastropik-pada-2022

Precision medicine (efpia.eu)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685222/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792453/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC85545

In Indonesia, as in many other nations, cancer stands as a major public health concern, with the most prevalent types including breast, cervical, lung, colorectal, and liver cancer. The country encounters distinct obstacles in cancer care, such as limited access to programs for early detection, a deficit in healthcare facilities and oncology specialists, and the prohibitive costs associated with treatment. Furthermore, a general lack of awareness regarding cancer prevention and the importance of early detection contributes to diagnoses at advanced stages and diminished survival rates. Consequently, the advancement of oncology in Indonesia is geared towards enhancing early detection and screening initiatives, raising public awareness about cancer, and improving the healthcare system along with making treatments more accessible and affordable. Additionally, there is an increasing inclination towards combining traditional and modern cancer treatment methods to offer comprehensive care to patients. The field of clinico-genomic research holds considerable promise for oncology in Indonesia by pinpointing genetic and molecular markers unique to the Indonesian populace that influence cancer susceptibility, progression, and response to treatment. Our studies aim to facilitate personalized treatment approaches, which could significantly enhance treatment efficacy and potentially lower death rates. Moreover, by elucidating the genetic characteristics of prevalent cancers in Indonesia, such as those of the breast, lung, and cervix, we can develop focused strategies for screening and prevention, ultimately leading to improved health outcomes.

Source

https://cdn.who.int/media/docs/default-source/country-profiles/ncds/idn_en.pdf?sfvrsn=fbb0cdfb_33&download=true

https://www.iccp-portal.org/system/files/plans/IDN_2020.pdf

https://databoks.katadata.co.id/datapublish/2023/07/03/bpjs-kesehatan-kucurkan-rp24-triliun-untuk-penyakit-katastropik-pada-2022

Precision medicine (efpia.eu)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685222/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792453/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC85545

Precision medicine in oncology

For the patient

Higher likelihood to demonstrate clinical benefit

Reduce adverse effects

Increase survival rate

For hospitals

More effective use of healthcare resources

Reduction in hospitalization rates

Better disease care management

For pharmaceuticals

Increase success rate of clinical trials

Improve efficiency in drug development

Cost reduction

The field of clinico-genomic research holds considerable promise for oncology in Indonesia by pinpointing genetic and molecular markers unique to the Indonesian populace that influence cancer susceptibility, progression, and response to treatment.7 Our studies aim to facilitate personalized treatment approaches, which could significantly enhance treatment efficacy and potentially lower death rates. Moreover, by elucidating the genetic characteristics of prevalent cancers in Indonesia, such as those of the breast, lung, and cervix, we can develop focused strategies for screening and prevention, ultimately leading to improved health outcomes.

For the patient

Higher likelihood to demonstrate clinical benefit

Reduce adverse effects

Increase survival rate

For hospitals

More effective use of healthcare resources

Reduction in hospitalization rates

Better disease care management

For pharmaceuticals

Increase success rate of clinical trials

Improve efficiency in drug development

Cost reduction

Precision medicine in oncology

The field of clinico-genomic research holds considerable promise for oncology in Indonesia by pinpointing genetic and molecular markers unique to the Indonesian populace that influence cancer susceptibility, progression, and response to treatment.7 Our studies aim to facilitate personalized treatment approaches, which could significantly enhance treatment efficacy and potentially lower death rates. Moreover, by elucidating the genetic characteristics of prevalent cancers in Indonesia, such as those of the breast, lung, and cervix, we can develop focused strategies for screening and prevention, ultimately leading to improved health outcomes.

Oncology, the branch of medicine dedicated to the study and treatment of cancer,

stands as a beacon of hope in the face of one of the most formidable challenges to human health.

Join the Journey towards Longevity with ONEASA

Discover sponsorship opportunities and join hands in unlocking longevity.

Discover

BIC Building 4th Floor, Jl. Teuku Cik Ditiro No.12,

Menteng, Central Jakarta, Indonesia 10350

© 2024 ONEASA. All rights reserved.

Be Our Sponsor

Be Our Partner

Be Our Researcher

Research Topics - Oncology

Advancing research for oncology Research

Join ONEASA’s dedicated research for elevating reproductive health through diversity and innovation.

Oncology, the branch of medicine dedicated to the study and treatment of cancer, stands as a beacon of hope in the face of one of the most formidable challenges to human health.

Join the Journey towards Longevity with ONEASA

Discover sponsorship opportunities and join hands in unlocking longevity.

Discover

BIC Building 4th Floor, Jl. Teuku Cik Ditiro No.12,
Menteng, Central Jakarta, Indonesia 10350

© 2024 ONEASA. All rights reserved.

BIC Building 4th Floor, Jl. Teuku Cik Ditiro No.12,
Menteng, Central Jakarta, Indonesia 10350

© 2024 ONEASA. All rights reserved.